Loading...
ABUS ARBUTUS BIOPHARMA CORP Business Restructuring 8-K Filing
Back
RBTS
BS
ARBUTUS BIOPHARMA CORP
(ABUS)
Follow
FY2023 8 K
View More
Back
RBTS
BS
ARBUTUS BIOPHARMA CORP
(ABUS)
Follow
FY2023 8 K
Filing:
8 K
Published on:
7 Nov '23
Presentation of Research Fi...
7 May '25
Conference Presentations
23 Apr '25
Management Changes
3 Apr '25
Financial Results
27 Mar '25
Patent Litigation
3 Mar '25
Board Restructuring
25 Feb '25
Financial Update
13 Jan '25
Clinical Trial Results
15 Nov '24
Q3 2024 Results
6 Nov '24
Clinical Data Presentation
15 Oct '24
Management Change
11 Oct '24
Regulation FD Disclosure
5 Aug '24
Financial Results and Corpo...
1 Aug '24
Clinical Trial Results
6 Jun '24
Clinical Trial Results
5 Jun '24
Shareholder Meeting Approval
28 May '24
Announcement of Abstract Ac...
22 May '24
Financial Results and Corpo...
2 May '24
Retirement of Chief Scienti...
2 May '24
Lawsuit Update
4 Apr '24
Financial Results and Corpo...
29 Feb '24
Financial Results
8 Jan '24
Management Changes
4 Jan '24
Poster Presentation and Cor...
9 Nov '23
Financial Results, Workforc...
7 Nov '23
Retirement and Appointment
7 Nov '23
Announcement of Data Presen...
11 Oct '23
Pipeline Updates
11 Sep '23
Financial Results and Corpo...
3 Aug '23
Clinical Trial Update
21 Jun '23
Clinical Trial Results
21 Jun '23
Announcement of Poster Pres...
7 Jun '23
Management Changes
30 May '23
Financial Results and Corpo...
4 May '23
Clinical Data Presentation
27 Apr '23
Other Events
25 Apr '23
Announcement of Abstract Ac...
18 Apr '23
Lawsuit against Pfizer and ...
4 Apr '23
Product Launch
16 Mar '23
Preclinical Data Announcement
14 Mar '23
Financial Results and Corpo...
2 Mar '23
Resignation of Director
27 Jan '23
Press Release
5 Jan '23
External Links:
SEC
AI Assistant
Close
ARBUTUS BIOPHARMA CORP
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.